Overview / Abstract: |
The development of immunotherapies, including ICIs and CAR-T cell agents, is improving survival for some patients with cancer, even in advanced cases. These agents are associated with novel irAEs that are monitored and managed differently than the more familiar standard chemotherapy toxicities. Collaboration among members of the oncology care team is necessary to ensure that all healthcare providers, patients, and caregivers are educated about irAEs and their management. For all members of the team to support optimal outcomes, clinicians need to continue to enhance their knowledge and skills regarding the latest guidelines and treatment. |
Expiration |
Nov 15, 2022 |
Discipline(s) |
Nurse Practitioner , Nursing CNE, Pharmacy CPE, Physician CME, Physician Assistant CME |
Format |
Online |
Credits / Hours |
1.5 |
Accreditation |
American Academy of CME, Inc |
Presenters / Authors / Faculty |
Paolo Caimi, MD Marcus Flores, Pharm.D., BCPS, BCOP Laura Wood, RN, MSN, OCN |
Activity Specialities / Related Topics |
Hematology, Oncology / Cancer / Radiation Therapy, Other |
Sponsors / Supporters / Grant Providers |
Merck |
Keywords / Search Terms |
American Academy of CME Immune related adverse events Cancer Oncology Hematology Interprofessional Free CE CME |